Zacks Research Has Negative Outlook for BDX Q3 Earnings

Becton, Dickinson and Company (NYSE:BDX) – Stock analysts at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for Becton, Dickinson and Company in a research report issued to clients and investors on Monday, June 23rd. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will earn $3.44 per share for the quarter, down from their prior forecast of $3.46. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q4 2025 earnings at $3.95 EPS, FY2025 earnings at $14.17 EPS, Q2 2026 earnings at $3.55 EPS, Q3 2026 earnings at $3.82 EPS, Q4 2026 earnings at $4.19 EPS, FY2026 earnings at $14.72 EPS, Q1 2027 earnings at $3.38 EPS, Q2 2027 earnings at $3.77 EPS and FY2027 earnings at $15.71 EPS.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating analysts’ consensus estimates of $3.28 by $0.07. The company had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter last year, the company earned $3.17 earnings per share.

A number of other brokerages also recently issued reports on BDX. Citigroup downgraded Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and cut their target price for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. The Goldman Sachs Group downgraded Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 target price for the company. in a research note on Friday, May 2nd. Wells Fargo & Company cut Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a report on Thursday, May 1st. William Blair cut Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a report on Thursday, May 1st. Finally, Stifel Nicolaus lowered their price target on Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Eight equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and an average price target of $219.22.

Becton, Dickinson and Company Trading Down 0.3%

BDX opened at $171.04 on Wednesday. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The stock has a market capitalization of $49.02 billion, a price-to-earnings ratio of 32.64, a PEG ratio of 1.30 and a beta of 0.25. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. The business has a fifty day moving average price of $177.66 and a 200 day moving average price of $210.22.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.43%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 79.39%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 479 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the transaction, the executive vice president now owns 4,887 shares in the company, valued at approximately $964,107.36. The trade was a 8.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP David Shan sold 1,166 shares of the business’s stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the transaction, the executive vice president now owns 4,575 shares in the company, valued at $783,194.25. This trade represents a 20.31% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.36% of the company’s stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several large investors have recently modified their holdings of BDX. Hillsdale Investment Management Inc. increased its position in shares of Becton, Dickinson and Company by 1.7% in the fourth quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier’s stock worth $694,000 after purchasing an additional 50 shares during the period. Northcape Wealth Management LLC boosted its position in shares of Becton, Dickinson and Company by 0.5% during the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock valued at $2,248,000 after purchasing an additional 51 shares in the last quarter. Alpha Omega Wealth Management LLC increased its position in Becton, Dickinson and Company by 5.7% in the first quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier’s stock worth $225,000 after buying an additional 53 shares in the last quarter. Brady Family Wealth LLC grew its position in shares of Becton, Dickinson and Company by 1.2% during the first quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier’s stock worth $989,000 after purchasing an additional 53 shares in the last quarter. Finally, Diversified Trust Co increased its holdings in Becton, Dickinson and Company by 4.7% during the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock worth $272,000 after purchasing an additional 53 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.